格隆汇12月4日丨重药控股(000950.SZ)公布，2025年前三季度利润分配预案：公司拟以2025年9月30日 享有利润分配权的股本总数1,712,778,096股（总股本1,728,184,696股扣除公司回购专户中持有的股份 15,406,600股）为基数，向全体股东每10股派发0.30元人民币现金（含税），分配总金额为51,383,342.88 元（含税），不送红股，不以公积金转增股本。 ...

近半年该股累计上榜龙虎榜14次，上榜次日股价平均跌0.88%，上榜后5日平均跌2.02%。 人民同泰(600829)今日跌停，全天换手率11.22%，成交额8.63亿元，振幅7.37%。龙虎榜数据显示，营 业部席位合计净卖出5105.98万元。 上交所公开信息显示，当日该股因日跌幅偏离值达-9.96%上榜，营业部席位合计净卖出5105.98万元。 证券时报·数据宝统计显示，上榜的前五大买卖营业部合计成交1.77亿元，其中，买入成交额为6313.31 万元，卖出成交额为1.14亿元，合计净卖出5105.98万元。 具体来看，第一大买入营业部及卖出营业部均为中信证券股份有限公司上海分公司，买入金额为 1770.34万元，卖出金额为3926.93万元。 1021.18 资金流向方面，今日该股主力资金净流出4921.21万元，其中，特大单净流出2410.07万元，大单资金净 流出2511.14万元。近5日主力资金净流入8701.70万元。 10月21日公司发布的三季报数据显示，前三季度公司共实现营业收入78.46亿元，同比增长2.19%，实现 净利润1.12亿元，同比下降45.69%。（数据宝） 人民同泰12月4日交 ...

格隆汇12月4日丨重药控股(000950.SZ)公布，2025年前三季度利润分配预案：公司拟以2025年9月30日 享有利润分配权的股本总数1,712,778,096股（总股本1,728,184,696股扣除公司回购专户中持有的股份 15,406,600股）为基数，向全体股东每10股派发0.30元人民币现金（含税），分配总金额为51,383,342.88 元（含税），不送红股，不以公积金转增股本。 ...

格隆汇12月4日｜重药控股公告，公司拟以2025年9月30日享有利润分配权的股本总数17.13亿股为基 数，向全体股东每10股派发0.30元人民币现金（含税），分配总金额为5138.33万元（含税），不送红 股，不以公积金转增股本。 ...

Group 1: Financial Performance - In Q3 2025, the company achieved an operating revenue of 622.11 million yuan, representing a year-on-year growth of 4.22% [2] - The net profit attributable to shareholders reached 38.4 million yuan, with a year-on-year increase of 31.41% [2] - The net profit excluding non-recurring items grew by 36.83% [2] Group 2: Business Collaboration and Expansion - Following its integration into the General Technology Group, the company has accelerated business collaboration with medical institutions, successfully opening 138 accounts across 25 provinces by the end of September 2025 [2] - The company has enhanced its creditworthiness, leading to broader financing channels and a noticeable decrease in financing costs [2] Group 3: Pharmaceutical Operations - The company is one of three national wholesale enterprises for narcotic and psychotropic drugs, holding regional wholesale qualifications in 15 provinces, with a sales network covering 31 provinces and autonomous regions [3] - The company has a competitive advantage in narcotic drug distribution in regions such as Sichuan, Chongqing, Guizhou, Qinghai, and Tibet [3] Group 4: Retail Operations - By the end of September 2025, the company operated retail pharmacies across 22 provinces, municipalities, and autonomous regions, including 210 community health pharmacies and 832 DTP prescription pharmacies [3] - The company plans to strengthen its retail omnichannel construction and enhance its nationwide network layout, focusing on multi-dimensional marketing services and patient management systems [3]

Core Viewpoint - 瑞康医药's stock experienced a significant increase, reaching the daily limit with a turnover rate of 24.58% and a transaction volume of 1.282 billion yuan, indicating strong market interest and volatility [2]. Trading Activity - The stock's price rose by 10.10%, leading to its inclusion on the Shenzhen Stock Exchange's watchlist for significant price deviation [2]. - Institutional investors net sold 22.4579 million yuan, while total net selling from brokerage seats amounted to 6.3127 million yuan [2]. - The top five brokerage seats accounted for a total transaction volume of 208 million yuan, with buying amounting to 89.6331 million yuan and selling at 118 million yuan, resulting in a net sell of 28.7706 million yuan [2]. Fund Flow - The stock saw a net outflow of 88.0528 million yuan from major funds, with large orders contributing to a net outflow of 53.1893 million yuan and big orders at 34.8636 million yuan [2]. - Over the past five days, the stock experienced a net inflow of 53.4196 million yuan [2]. Margin Trading - As of December 3, the margin trading balance for 瑞康医药 was 203 million yuan, with a financing balance of 202 million yuan and a securities lending balance of 484.7 thousand yuan [2]. - In the last five days, the financing balance decreased by 20.2736 million yuan, representing a decline of 9.12%, while the securities lending balance increased by 55.3 thousand yuan, showing a rise of 12.89% [2].

南京医药集团股份有限公司 关于公司全称、注册资本变更登记及《公司章程》备案完成的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 重要内容提示： ● 变更后的公司全称：南京医药集团股份有限公司（以下简称"公司"），英文名称变更为"Nanjing Pharmaceutical Group Company Limited"。证券简称、证券代码均保持不变。 证券代码：600713 证券简称：南京医药 编号：ls2025-153 债券代码：110098 债券简称：南药转债 ● 变更后的公司注册资本：1,308,929,289元。 一、本次变更的基本情况 2025年10月29日，公司第十届董事会第四次会议审议通过《关于修订〈南京医药股份有限公司章程〉相 关条款并取消监事会、变更公司全称及注册资本的议案》，同意公司取消监事会，由董事会审计与风险 控制委员会行使《公司法》规定的监事会职权，《南京医药股份有限公司监事会议事规则》相应废止。 同意变更公司全称为"南京医药集团股份有限公司"，英文名称变更为"Nanjing Pharmaceut ...

Group 1 - The core point of the article highlights that Ruikang Pharmaceutical has achieved a significant trading volume of 1.068 billion yuan, marking the highest level since December 19, 2022 [2] - The latest stock price of Ruikang Pharmaceutical has increased by 8.52%, with a turnover rate of 20.54% [2] - The previous trading day saw a total trading volume of 362 million yuan for the stock [2] Group 2 - Ruikang Pharmaceutical Group Co., Ltd. was established on September 21, 2004, with a registered capital of 1.50471 billion yuan [2]

展望后市，沪指今日回踩3888点附近支撑后未能有效企稳，短期仍处于3850-3950点区间震荡格局；警 惕高估值中小票的流动性风险，以及海外美联储政策预期波动对A股的传导影响。 上证指数收跌0.51%报3878点，深证成指跌0.78%，创业板指跌1.12%，科创50跌0.89%，A股全天成交 1.68万亿元，上日成交1.61万亿元，显示市场分歧有所加大。 医药商业板块近期表现活跃，海王生物6连板涨停。消息面上，近日，中国疾控中心相关负责人介绍本 轮流感最新情况，预计全国在12月上中旬达峰的可能性较大，未来6到8周流感防控不能放松。朱雀三号 遥一运载火箭发射升空并实现二级入轨，虽回收试验失败，但为后续可重复使用技术积累数据，对商业 航天板块形成差异化影响。 《大象财经》 -- 河南卫视财经新主张: 把握最新财经热点,传播权威政策解读, 记录真实财经故事,关注全民消费安全, 架起政企沟通桥梁,助力地方经济腾飞。 ...

（文章来源：每日经济新闻） 每经AI快讯，12月4日，医药商业板块短线走低，人民同泰跌超9%，合富中国、开开实业、建发致新、 达嘉维康等跟跌。 ...